A US based Health Insurance Provider makes investments in healthcare companies from an evergreen investment fund. Allocation sizes are highly varied, but are most often $3-5 million. While the firm is open to opportunities globally, the organization only invests in companies that are targeting the US healthcare market (including companies with products that have been commercialized in other markets and are seeking capital to expand into the US market).
The firm invests in transformative medical technologies that will lower the cost of care provision, and has previously made investments in healthcare IT and in wearable sensors for elderly patients. The firm only invests in companies that have attained regulatory approval for their products, or which do not require approval. The fund does not invest in therapeutics, but is open to investing in diagnostic technologies that will lower the cost of care. In the medical device sector, the firm is generally not interested in invasive devices such as implantable.
While the firm is open to investing in any indication area, the firm’s focus is on population health and the firm is therefore primarily interested in indications with a large number of patients, including cancer, diseases of the nervous system, and diabetes.
The firm invests in both pre-revenue companies and companies with existing revenues, but does not invest in companies that still face regulatory barriers to attaining revenue. The firm has long-term horizons for investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment